Observational studyAddiction (Abingdon, England)2021
The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Observational study in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 52 citations in OpenAlex.
- Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial.Annals of internal medicine · 2026Trial
- Prescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial.The International journal on drug policy · 2025Trial
- Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.Contemporary clinical trials · 2024Trial
- War-related displacement, conflict intensity, and treatment delivery factors in opioid agonist maintenance treatment discontinuation following Russia's invasion of Ukraine: a national cohort study.The Lancet regional health. Europe · 2026Article
- Exploring multi-level barriers and human-centered solutions to expand methadone for HIV prevention among people who inject drugs in Kyrgyzstan.Journal of substance use and addiction treatment · 2026Article
- Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine.The International journal on drug policy · 2026Article
- Probation as a targeted entry point for scaling up opioid agonist therapies in Moldova using a modified screening, brief intervention and referral to treatment strategy.PLOS global public health · 2026Article
- Seventeen years of experience: a retrospective cohort analysis of methadone maintenance treatment program patterns in Georgia.Harm reduction journal · 2025Article
- Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia.Drug and alcohol dependence · 2025Article
- Exploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan.Journal of substance use and addiction treatment · 2025Article
- Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States.The International journal on drug policy · 2025Article
- Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).Contemporary clinical trials · 2025Article
- Early experiences and impacts of a fentanyl powder safer supply program in Vancouver, Canada: a qualitative study.The American journal of drug and alcohol abuse · 2025Article
- The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.Drug and alcohol dependence · 2024Article
- Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine.International journal of mental health and addiction · 2024Article
- The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.Journal of substance use and addiction treatment · 2024Article
- Article
- Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia.The International journal on drug policy · 2024Article
- Outcome in methadone maintenance treatment of immigrants from the former Union of Soviet Socialist Republics.Harm reduction journal · 2024Article
- Impact of the Russian invasion on opioid agonist therapy programs in Ukraine: A qualitative study.Drug and alcohol dependence · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsUkraine's HIV epidemic remains concentrated among opioid-dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost-effective HIV prevention strategies, but remain under-scaled. This study aimed to measure the association between dose and type of OAT prescribed and treatment retention.
designObservational longitudinal cohort study. PARTICIPANTS AND
settingPatients (n = 15 290) prescribed OAT throughout Ukraine from 2004 through 2016. MEASUREMENTS: Data were analyzed using time-event strategies to estimate cumulative treatment retention, defined as time to OAT discontinuation. Cumulative retention proportions at 1, 12 and 36 months were assessed for outcomes. Cox regression with log-rank likelihood assessed independent predictors of treatment discontinuation.
findingsThe proportion prescribed high (MMT: > 85 mg; BMT: ≥ 16 mg), medium (MMT: > 40-85 mg; BMT: > 6-15 mg) and low (MMT: ≤ 40 mg; BMT: ≤ 6 mg) dosages was 25, 43 and 32%, respectively. Retention was significantly higher for BMT than MMT both at 12 (89 versus 75%) and 36 months (80 versus 56%). Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively. Independent predictors associated with 12-month OAT discontinuation were medium [adjusted hazard ratio (aHR) = 2.23; 95% confidence limit (CL) = 1.95-2.54] and low (aHR = 4.96; 95% CL = 4.37-5.63) OAT dosage relative to high dosage, male sex (aHR = 1.27; 95% CL = 1.14-1.41), MMT relative to BMT prescription (aHR = 1.57; 95% CL = 1.32-1.87) and receiving OAT in general (aHR = 1.22; 95% CL = 1.02-1.46) or tuberculosis (aHR = 1.43; 95% CL = 1.10-1.85) hospitals, relative to specialty addiction treatment and AIDS center settings. Lower dosages contributed more to dropout especially at 1 month (aHR 3.12; 95% CL = 2.21-4.41 and aHR 7.71; 95% CL = 5.51-10.79 for medium and low dosages, respectively). Younger age was significantly associated with OAT discontinuation only at 36 months (aHR = 1.08; 95% CI = 1.02-1.15).
conclusionsHigher dosages of opioid agonist therapies, especially for methadone maintenance treatment patients, appear to be associated with higher levels of treatment retention in Ukraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.